Allergy Therapeutics PLC Grant of Options under Long Term Incentive Plan (9885G)

TIDMAGY

RNS Number : 9885G

Allergy Therapeutics PLC

25 November 2015

25 November 2015

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Grant of Options under Long Term Incentive Plan

Allergy Therapeutics plc confirms that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2015, details of which were announced on 19 December 2012, have been met. Consequently, Allergy Therapeutics has today granted certain of its directors nil cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP as follows:

 
 Director                    Number of Ordinary     Total number         Total remaining 
                                 Shares over      of Ordinary Shares    number of Ordinary 
                                which Options     over which Options   Shares provisionally 
                                   granted             granted            awarded under 
                                                                              LTIPs 
 
 Manuel Llobet, 
  Chief Executive Officer         624,024              624,024              2,595,000 
 Ian Postlethwaite, 
  Finance Director                312,012              475,512              1,297,500 
 

The Options have been granted in accordance with the LTIP rules and can be exercisable at nil cost between 25 December 2015 and 25 December 2018.

For further information:

 
                                                     +44 (0) 1903 
 Allergy Therapeutics                                 845 820 
 Manuel Llobet, Chief Executive Officer 
 Ian Postlethwaite, Finance Director 
 
                                                     [phone] 
 Panmure Gordon                                       2500 
 Freddy Crossley / Peter Steel / Duncan Monteith, 
  Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
                                                     [phone] 
 FTI Consulting                                       1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP43 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSZMMZMNKRGKZM

(END) Dow Jones Newswires

November 25, 2015 13:07 ET (18:07 GMT)